Printer Friendly

United States : Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis.

Takeda Pharmaceutical Company Limited today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy status to the company s investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis. This is the first proteasome inhibitor and first investigational therapy for AL amyloidosis to receive Breakthrough Therapy designation.

The development program for ixazomib in this indication progressed directly from a Phase 1 to a Phase 3 clinical trial, TOURMALINE-AL1, which is currently evaluating ixazomib plus dexamethasone in patients with relapsed or refractory AL amyloidosis. This is the only Phase 3 trial for relapsed or refractory AL amyloidosis and it is recruiting globally.

Breakthrough Therapy designation is intended to expedite the development and review of new medicines to treat serious or life-threatening conditions. Breakthrough Therapy designation requires preliminary clinical evidence indicating that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. The data used to support this designation will be presented at the American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco Abstract 3450: Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL) .

Patients with AL amyloidosis face a debilitating disease that can affect many of their organs and tissues. The Breakthrough Therapy designation for ixazomib is a major milestone in the development of new treatment options for patients battling this rare and aggressive disease, said Raymond L. Comenzo, M.D., Director, Blood Bank and Stem Cell Processing Laboratory and Professor, Tufts University School of Medicine. We are encouraged by positive preliminary data evaluating use of ixazomib in the treatment of patients with relapsed or refractory AL amyloidosis.

Ixazomib is a breakthrough drug showing activity and organ improvement in most of these heavily pretreated AL amyloidosis patients, said Professor Giampaolo Merlini, Director, Center for Research and Treatment of Systemic Amyloidosis, University of Pavia, Italy.

AL amyloidosis is a rare and aggressive protein misfolding disorder with fewer than 3,000 cases diagnosed in the U.S. every year. It is characterized by the deposition of amyloid in bodily organs and tissues. While AL amyloidosis can affect different organs in different people, it frequently affects the heart, kidneys, liver, spleen, nervous system, and gastrointestinal tract.

2014 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2014 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Dec 3, 2014
Previous Article:United States : Alaska Airlines' Regional Partner Horizon Air Achieves International Safety Standard.
Next Article:United States : $6.5 Million Arizona Acquisition Loan Arranged by Marcus & Millichap Capital Corp.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters